|
|
|
| Basiliximab application on liver recipients, a meta-analysis of randomized controlled trials |
| Guo-Qing Zhang, Cheng-Shuo Zhang, Ning Sun, Wu Lv, Bao-Min Chen and Jia-Lin Zhang |
Shenyang, China
Author Affiliations: Department of Hepatobiliary and Transplantation Surgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China (Zhang GQ, Zhang CS, Sun N, Lv W, Chen BM and Zhang JL); Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450003, China (Zhang GQ)
Corresponding Author: Jia-Lin Zhang, MD, PhD, Department of Hepatobiliary and Transplantation Surgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China (Tel: +86-24-83283308; Fax: +86-24-83282997; Email: jlz2000@yeah.net) |
|
|
|
Abstract BACKGROUND: The benefits of the application of basiliximab induction therapy in liver transplantation are not clear. The present meta-analysis was to evaluate the pros and cons of basiliximab use in liver transplantation.
DATA SOURCES: We searched the associated publications in English from July 1998 to December 2015 in the following databases: Medline, PubMed, Ovid, Embase, Web of Science and Cochrane Library.
RESULTS: Basiliximab significantly decreased the incidence of de novo diabetes mellitus after liver transplantation (RR=0.56; 95% CI: 0.34-0.91; P=0.02). Subgroup analysis showed that basiliximab in combination with steroids-free immunosuppressant significantly decreased the incidence of biopsy-proven acute rejection (RR=0.62; 95% CI: 0.39-0.97; P=0.04) and new-onset hypertension (RR=0.62; 95% CI: 0.42-0.93; P=0.02).
CONCLUSIONS: Basiliximab may be effective in reducing de novo diabetes mellitus. What is more, basiliximab in combination with steroids-free immunosuppressant shows statistically benefit to reduce biopsy-proven acute rejection and de novo hypertension.
|
|
|
|
|
|
|
|
|
2017, Vol. 16 
